Literature DB >> 14673384

Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers.

Kathleen Maksimowicz-McKinnon1, Deepak L Bhatt, Leonard H Calabrese.   

Abstract

PURPOSE OF REVIEW: Inflammatory vascular diseases are initiated and perpetuated by the interaction of immune cells with cells of the affected vessel wall. This is directed by a network of chemical messengers, which, in a state of vascular health, exist as balanced but opposing forces. Our understanding of this highly complex process has advanced significantly in the last several decades. The detection of vascular inflammation and monitoring of this activity have long been attempted in systemic vasculitis, and, more recently, in atherosclerosis. Markers of vascular inflammation used thus far have been of limited value; few provide both adequate sensitivity and specificity for any particular disease. New insights into the pathophysiology of vascular inflammation have identified other potential markers that may improve detection and monitoring of these conditions. RECENT
FINDINGS: Immunomodulatory mediators of the inflammatory cascade have been identified, and their roles are being defined. There are recent data that implicate various cytokines, proteases, adhesion molecules, and acute phase proteins as participants in the generation of vascular inflammation.
CONCLUSION: The pursuit of highly sensitive and specific markers of vascular inflammation has produced a wealth of information that has been instrumental in advancing our comprehension of this complex process. Further studies will establish the role of these new markers in the diagnosis, monitoring, and prognostication of inflammatory vascular disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673384     DOI: 10.1097/00002281-200401000-00005

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  12 in total

1.  Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Zhe Dong; Tingting Wu; Weidong Qin; Chuankai An; Zhihao Wang; Mingxiang Zhang; Yun Zhang; Cheng Zhang; Fengshuang An
Journal:  Mol Med       Date:  2011-09-21       Impact factor: 6.354

2.  Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Heidemarie Becker; Christian Maaser; Eva Mickholz; Anke Dyong; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

Review 3.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

4.  IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents.

Authors:  Valderilio Feijó Azevedo; J R Faria-Neto; Andrea Stinghen; Pedro G Lorencetti; Wagner P Miller; Beatriz P Gonçalves; Carla C Szyhta; Roberto Pecoits-Filho
Journal:  Rheumatol Int       Date:  2013-01-08       Impact factor: 2.631

5.  N-glycans of core2 beta(1,6)-N-acetylglucosaminyltransferase-I (C2GnT-I) but not those of alpha(1,3)-fucosyltransferase-VII (FucT-VII) are required for the synthesis of functional P-selectin glycoprotein ligand-1 (PSGL-1): effects on P-, L- and E-selectin binding.

Authors:  Maëlle Prorok-Hamon; Frédéric Notel; Sylvie Mathieu; Claire Langlet; Minoru Fukuda; Assou El-Battari
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

6.  Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease.

Authors:  M Libra; S S Signorelli; Y Bevelacqua; P M Navolanic; V Bevelacqua; J Polesel; R Talamini; F Stivala; M C Mazzarino; G Malaponte
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

7.  C-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels.

Authors:  Thomas O Obisesan; Christiaan Leeuwenburgh; Tracey Phillips; Robert E Ferrell; Dana A Phares; Steven J Prior; James M Hagberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-22       Impact factor: 8.311

Review 8.  Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

Authors:  Matthew A Silva; Jennifer L Donovan; Pritesh J Gandhi; Gregory A Volturo
Journal:  Vasc Health Risk Manag       Date:  2006

9.  Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.

Authors:  Hanna Przepiera-Będzak; Katarzyna Fischer; Marek Brzosko
Journal:  Int J Mol Sci       Date:  2016-08-03       Impact factor: 5.923

10.  Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study.

Authors:  Tae-Min Rhee; Ji Hyun Lee; Eue-Keun Choi; Kyung-Do Han; HyunJung Lee; Chan Soon Park; Doyeon Hwang; So-Ryoung Lee; Woo-Hyun Lim; Si-Hyuck Kang; Myung-Jin Cha; Youngjin Cho; Il-Young Oh; Seil Oh
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.